{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T20:19:37Z","timestamp":1771877977001,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,12,18]],"date-time":"2015-12-18T00:00:00Z","timestamp":1450396800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1007\/s40265-015-0527-2","type":"journal-article","created":{"date-parts":[[2015,12,18]],"date-time":"2015-12-18T09:34:55Z","timestamp":1450431295000},"page":"135-146","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Tiotropium\/Olodaterol: A Review in COPD"],"prefix":"10.1007","volume":"76","author":[{"given":"Sohita","family":"Dhillon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,12,18]]},"reference":[{"key":"527_CR1","unstructured":"World Health Organization. Chronic respiratory diseases: chronic obstructive pulmonary disease. 2015. http:\/\/www.who.int\/respiratory\/copd\/en\/ . Accessed 30 Nov 2015."},{"key":"527_CR2","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD. 2015. http:\/\/www.goldcopd.org\/ . Accessed 30 Nov 2015."},{"key":"527_CR3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1465-9921-14-49","volume":"14","author":"DP Tashkin","year":"2013","unstructured":"Tashkin DP, Ferguson GT. Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir Res. 2013;14:49.","journal-title":"Respir Res"},{"key":"527_CR4","unstructured":"Boehringer Ingelheim Pharmaceuticals. Stiolto\u2122 Respimat\u00ae (tiotropium bromide and olodaterol): US prescribing Information. 2015. http:\/\/www.fda.gov\/ . Accessed 30 Nov 2015."},{"key":"527_CR5","unstructured":"European Medicines Agency. Spiolto Respimat (tiotropium bromide and olodaterol): summary of product characteristics. 2015. http:\/\/mri.medagencies.org\/Human\/Product\/Details\/44258 . Accessed 30 Nov 2015."},{"key":"527_CR6","volume-title":"Spiolto Respimat 28 puffs: Japanese prescribing information","author":"Boehringer Ingelheim","year":"2015","unstructured":"Ingelheim Boehringer. Spiolto Respimat 28 puffs: Japanese prescribing information. Tokyo: Nippon Boehringer Ingelheim Co., Ltd.; 2015."},{"issue":"15","key":"527_CR7","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1007\/s40265-014-0307-4","volume":"74","author":"GM Keating","year":"2014","unstructured":"Keating GM. Tiotropium Respimat\u00ae Soft Mist\u2122 inhaler: a review of its use in chronic obstructive pulmonary disease. Drugs. 2014;74(15):1801\u201316.","journal-title":"Drugs."},{"issue":"6","key":"527_CR8","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s40265-015-0371-4","volume":"75","author":"ED Deeks","year":"2015","unstructured":"Deeks ED. Olodaterol: a review of its use in chronic obstructive pulmonary disease. Drugs. 2015;75(6):665\u201373.","journal-title":"Drugs."},{"key":"527_CR9","unstructured":"European Medicines Agency. Spiolto Respimat 2.5 microgram\/2.5 microgram, inhalation solution (tiotropium and olodaterol): public assessment report scientific discussion. 2015. http:\/\/mri.medagencies.org\/Human\/Product\/Details\/44258 . Accessed 30 Nov 2015."},{"issue":"5\u20136","key":"527_CR10","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/0024-3205(93)90312-Q","volume":"52","author":"B Disse","year":"1993","unstructured":"Disse B, Reichl R, Speck G, et al. Ba 679 BR, a novel long-acting anticholinergic bronchodilator. Life Sci. 1993;52(5\u20136):537\u201344.","journal-title":"Life Sci"},{"issue":"4","key":"527_CR11","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1513\/pats.200504-043SR","volume":"2","author":"KE Belmonte","year":"2005","unstructured":"Belmonte KE. Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2(4):297\u2013304.","journal-title":"Proc Am Thorac Soc."},{"issue":"21","key":"527_CR12","doi-asserted-by":"crossref","first-page":"8746","DOI":"10.1021\/jm401219y","volume":"56","author":"CS Tautermann","year":"2013","unstructured":"Tautermann CS, Kiechle T, Seeliger D, et al. Molecular basis for the long duration of action and kinetic selectivity of tiotropium for the muscarinic M3 receptor. J Med Chem. 2013;56(21):8746\u201356.","journal-title":"J Med Chem"},{"issue":"2","key":"527_CR13","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1124\/jpet.112.194456","volume":"343","author":"DA Sykes","year":"2012","unstructured":"Sykes DA, Dowling MR, Leighton-Davies J, et al. The influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium. J Pharmacol Exp Ther. 2012;343(2):520\u20138.","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"527_CR14","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0026-895X(25)10204-6","volume":"45","author":"EB Haddad","year":"1994","unstructured":"Haddad EB, Mak JC, Barnes PJ. Characterization of [3H]Ba 679 BR, a slowly dissociating muscarinic antagonist, in human lung: radioligand binding and autoradiographic mapping. Mol Pharmacol. 1994;45(5):899\u2013907.","journal-title":"Mol Pharmacol"},{"issue":"6 Pt 1","key":"527_CR15","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1164\/ajrccm.150.6.7952627","volume":"150","author":"T Takahashi","year":"1994","unstructured":"Takahashi T, Belvisi MG, Patel H, et al. Effect of Ba 679 BR, a novel long-acting anticholinergic agent, on cholinergic neurotransmission in guinea pig and human airways. Am J Respir Crit Care Med. 1994;150(6 Pt 1):1640\u20135.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"527_CR16","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.pupt.2010.03.003","volume":"23","author":"M Cazzola","year":"2010","unstructured":"Cazzola M, Molimard M. The scientific rationale for combining long-acting \u03b22-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther. 2010;23(4):257\u201367.","journal-title":"Pulm Pharmacol Ther"},{"issue":"7","key":"527_CR17","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1183\/09031936.93.06071031","volume":"6","author":"FP Maesen","year":"1993","unstructured":"Maesen FP, Smeets JJ, Costongs MA, et al. Ba 679 Br, a new long-acting antimuscarinic bronchodilator: a pilot dose-escalation study in COPD. Eur Respir J. 1993;6(7):1031\u20136.","journal-title":"Eur Respir J"},{"issue":"9","key":"527_CR18","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1183\/09031936.95.08091506","volume":"8","author":"FP Maesen","year":"1995","unstructured":"Maesen FP, Smeets JJ, Sledsens TJ, et al. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study Group. Eur Respir J. 1995;8(9):1506\u201313.","journal-title":"Eur Respir J."},{"issue":"2","key":"527_CR19","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1183\/09031936.02.00269802","volume":"19","author":"R Casaburi","year":"2002","unstructured":"Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002;19(2):217\u201324.","journal-title":"Eur Respir J"},{"issue":"15","key":"527_CR20","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1056\/NEJMoa0805800","volume":"359","author":"DP Tashkin","year":"2008","unstructured":"Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543\u201354.","journal-title":"N Engl J Med"},{"issue":"1","key":"527_CR21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1124\/jpet.110.167007","volume":"334","author":"T Bouyssou","year":"2010","unstructured":"Bouyssou T, Casarosa P, Naline E, et al. Pharmacological characterization of olodaterol, a novel inhaled \u03b22-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models. J Pharmacol Exp Ther. 2010;334(1):53\u201362.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"527_CR22","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1124\/jpet.111.179259","volume":"337","author":"P Casarosa","year":"2011","unstructured":"Casarosa P, Kollak I, Kiechle T, et al. Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol. J Pharmacol Exp Ther. 2011;337(3):600\u20139.","journal-title":"J Pharmacol Exp Ther"},{"key":"527_CR23","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2147\/COPD.S61717","volume":"9","author":"GT Ferguson","year":"2014","unstructured":"Ferguson GT, Feldman GJ, Hofbauer P, et al. Efficacy and safety of olodaterol once daily delivered via Respimat in patients with GOLD 2-4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis. 2014;9:629\u201345.","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"527_CR24","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2147\/COPD.S62502","volume":"9","author":"A Koch","year":"2014","unstructured":"Koch A, Pizzichini E, Hamilton A, et al. Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat\u00ae versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis. 2014;9:697\u2013714.","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"527_CR25","unstructured":"Troost J, Pivovarova A, Kunz C, et al. Evaluation of the effects of the long-acting \u03b22-agonist olodaterol on the QT and QTc interval in healthy subjects [abstract no. B24]. Am J Respir Crit Care Med. 2013;187(Meeting abstracts):A2603."},{"key":"527_CR26","unstructured":"Smit M, Zuidhof A, Bos S, et al. Effects of olodaterol and tiotropium on lipopolysaccharide-induced airway hyperresponsiveness and inflammation [abstract no. A60]. Am J Respir Care Med. 2013;187(Meeting abstracts):A1955."},{"key":"527_CR27","doi-asserted-by":"crossref","unstructured":"Bouyssou T, Schnapp A, Casarosa P, et al. Addition of the new once-daily LABA BI 1744 to tiotropium results in superior bronchoprotection in pre-clinical models [abstract no. C41]. Am J Respir Crit Care Med. 2010;181(Meeting abstracts):A4445.","DOI":"10.1164\/ajrccm-conference.2010.181.1_MeetingAbstracts.A4445"},{"issue":"7","key":"527_CR28","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.bbadis.2012.03.002","volume":"1822","author":"M Profita","year":"2012","unstructured":"Profita M, Bonanno A, Montalbano AM, et al. \u03b22 long-acting and anticholinergic drugs control TGF-\u03b21-mediated neutrophilic inflammation in COPD. Biochim Biophys Acta. 2012;1822(7):1079\u201389.","journal-title":"Biochim Biophys Acta"},{"key":"527_CR29","unstructured":"Maltais F, Beck E, Webster D, et al. Four weeks once daily treatment with tiotropium+olodaterol (BI 1744) fixed dose combination compared with tiotropium in COPD patients [abstract no. 5557]. In: European Respiratory Society Annual Conference. 2010."},{"issue":"9","key":"527_CR30","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s12325-015-0239-8","volume":"32","author":"R Aalbers","year":"2015","unstructured":"Aalbers R, Maleki-Yazdi MR, Hamilton A, et al. Randomized, double-blind, dose-finding study for tiotropium when added to olodaterol, administered via the Respimat\u00ae Inhaler in patients with chronic obstructive pulmonary disease. Adv Ther. 2015;32(9):809\u201322.","journal-title":"Adv Ther."},{"issue":"4","key":"527_CR31","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/jcph.215","volume":"54","author":"JM Hohlfeld","year":"2014","unstructured":"Hohlfeld JM, Sharma A, van Noord JA, et al. Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease. J Clin Pharmacol. 2014;54(4):405\u201314.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"527_CR32","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1183\/09031936.00136014","volume":"45","author":"R Buhl","year":"2015","unstructured":"Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). Eur Respir J. 2015;45(4):969\u201379.","journal-title":"Eur Respir J"},{"key":"527_CR33","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.pupt.2015.04.002","volume":"32","author":"KM Beeh","year":"2015","unstructured":"Beeh KM, Westerman J, Kirsten AM, et al. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2015;32:53\u20139.","journal-title":"Pulm Pharmacol Ther"},{"issue":"10","key":"527_CR34","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.rmed.2015.08.002","volume":"109","author":"D Singh","year":"2015","unstructured":"Singh D, Ferguson GT, Bolischeck J. Tiotropium+olodaterol shows clinically meaningful improvements in quality of life. Respir Med. 2015;109(10):1312\u20139.","journal-title":"Respir Med"},{"key":"527_CR35","doi-asserted-by":"crossref","unstructured":"Beeh KM, Derom E, Echave-Sustaeta, et al. ENERGITO: efficacy and safety of once-daily combined tiotropium\u00a0+\u00a0olodaterol versus twice-daily combined fluticasone propionate + salmeterol [abstract no. PA4366]. In: European Respiratory Society Annual Congress. 2015.","DOI":"10.1183\/13993003.congress-2015.PA4366"},{"key":"527_CR36","unstructured":"O\u2019Donnell D, Casaburi R, De Sousa D, et al. Effects of 6\u00a0weeks\u2019 treatment with once-daily tiotropium and olodaterol fixed-dose combination on inspiratory capacity and exercise endurance in patients with COPD: the MORACTO\u2122 studies [abstract no. P609]. Am J Respir Crit Care Med. 2015;191(Meeting abstracts):A3972."},{"issue":"Suppl 2","key":"527_CR37","doi-asserted-by":"crossref","first-page":"A186","DOI":"10.1136\/thoraxjnl-2014-206260.378","volume":"69","author":"F Maltais","year":"2014","unstructured":"Maltais F, Galdiz Iturri JB, Kirsten A, et al. Effects of 12\u00a0weeks of once-daily tiotropium and olodaterol fixed-dose combination on exercise endurance in patients with COPD [abstract no. P250]. Thorax. 2014;69(Suppl 2):A186\u20137.","journal-title":"Thorax"},{"issue":"6","key":"527_CR38","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s12325-015-0218-0","volume":"32","author":"GT Ferguson","year":"2015","unstructured":"Ferguson GT, Flezar M, Korn S, et al. Efficacy of tiotropium\u00a0+\u00a0olodaterol in patients with chronic obstructive pulmonary disease by initial disease severity and treatment intensity: a post hoc analysis. Adv Ther. 2015;32(6):523\u201336.","journal-title":"Adv Ther."},{"key":"527_CR39","doi-asserted-by":"crossref","unstructured":"Derom E, Korn S, Hamilton A, et al. Efficacy of tiotropium and olodaterol fixed-dose combination in patients with COPD on \u03b2-blockers [abstract no. PA995 plus poster]. In: European Respiratory Society International Annual Congress. 2015.","DOI":"10.1183\/13993003.congress-2015.PA995"},{"key":"527_CR40","unstructured":"Ichinose M, Takizawa A, Hamilton A, et al. Efficacy and safety of tiotropium and olodaterol fixed-dose combination via the Respimat\u00ae in COPD patients: Japanese subgroup analysis [abstract no. 120]. In: Congress of Asia Pacific Society of Respirology. 2015."},{"key":"527_CR41","unstructured":"Bai C, Buhl R, Lee SH, et al. Lung function with tioitropium plus olodaterol in East Asian patients with chronic obstructive pulmonary disease [abstract no. 701]. In: Congress of Asia Pacific Society of Respirology. 2015."},{"issue":"3","key":"527_CR42","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1164\/rccm.201310-1863PP","volume":"189","author":"PW Jones","year":"2014","unstructured":"Jones PW, Beeh KM, Chapman KR, et al. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med. 2014;189(3):250\u20135.","journal-title":"Am J Respir Crit Care Med"},{"key":"527_CR43","unstructured":"Buhl R, Tetzlaff K, Korducki L, et al. Pooled safety analysis of adjudicated serious adverse events with the fixed-dose combination of tiotropium\u00a0+\u00a0olodaterol [abstract no. P523]. Am J Respir Crit Care Med. 2015;191(Meeting abstracts):A5756."},{"key":"527_CR44","unstructured":"Bai C, Buhl R, Lee SH, et al. Safety of once-daily tiotropium olodaterl via Respimat in East Asian patients with chronic obstructive pulmonary disease [abstract no. 748]. In: Congress of Asia Pacific Society of Respirology. 2015."},{"issue":"5","key":"527_CR45","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/bcp.12545","volume":"79","author":"D Singh","year":"2015","unstructured":"Singh D. New combination bronchodilators for chronic obstructive pulmonary disease: current evidence and future perspectives. Br J Clin Pharmacol. 2015;79(5):695\u2013708.","journal-title":"Br J Clin Pharmacol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0527-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-015-0527-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0527-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T21:19:01Z","timestamp":1748726341000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-015-0527-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,18]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["527"],"URL":"https:\/\/doi.org\/10.1007\/s40265-015-0527-2","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,18]]}}}